MILESTONE (MMD): Milestone Medical Receives CE Mark for the Intra-Articular Instrument - raport 21

Milestone Medical Inc. receives CE Mark Approval for Intra-Articular Instrument

The Board of Directors of Milestone Medical Inc. (WAR: MMD, the “Company”, “Issuer”), today announced the Company has received CE Mark regulatory approval to market and sell its intra-articular instrument in Europe.

Regulatory approval in Europe for this instrument is validation of the Company’s technology and allows the Issuer to move forward with its plans to commercialize the technology in Europe. The Company is now in the process of evaluating potential strategic partners to distribute its intra-articular instrument in Europe. The Issuer believes it is well positioned to enter this multi-billion dollar market since conventional injections are painful, a problem eliminated with the Company’s instrument, and not always efficacious, as doctors often fail to locate the intra-articular space or use inappropriate volumes of hyaluronic acid.

The Issuer’s injection technology is based on a patented Dynamic Pressure Sensing® system (DPS®), intended to measure the density of body tissue and thus help a clinician know the location of a hypodermic needle during an injection. The system utilizes computer controlled technology to provide real-time feedback to the medical practitioner and identify with precision when a needle has reached the location where a drug should be administered to a patient. It has the added advantage in other applications of controlling the pain that patients typically associate with injections.

Legal basis: Section 3.1 of the Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect Market".

Osoby reprezentujące spółkę:
Leonard Osser - CEO
Joseph D'Agostino - CFO